Nitroparacetamol (NCX-701) and Pain: First in a Series of Novel Analgesics
- 1 September 2007
- journal article
- review article
- Published by Wiley in CNS Drug Reviews
- Vol. 13 (3), 279-295
- https://doi.org/10.1111/j.1527-3458.2007.00016.x
Abstract
The combination of numerous classic drugs with nitric oxide donors has led to the development of new compounds with promising therapeutic activities in a great variety of situations, including cardiovascular and respiratory systems, ocular pressure, inflammation, and pain. One of the first compounds developed was NCX-701 or nitroparacetamol, resulting from the combination of paracetamol, a classic and popular analgesic used in a great number of over-the-counter medications because of its antipyretic and analgesic properties, and a nitrooxybutyroyl moiety, which releases nitric oxide at a low but steady level. Although paracetamol is devoid of most of the gastrointestinal toxicity associated with aspirin-like drugs, this type of compounds was first designed to take advantage of the cytoprotective properties of nitric oxide when released at low concentrations. However, the combination of these molecules also resulted in an unexpected enhancement of the analgesic activity of paracetamol. In fact, NCX-701 has been shown to be effective in acute nociception as well as in neuropathic pain, situations in which paracetamol and other COX inhibitors are devoid of any effect. In addition, NCX-701 is more potent and, in some circumstances, more effective than its parent compound in different models of inflammatory pain. Furthermore, whereas paracetamol lacks any effective antiinflammatory action, NCX-701 might reduce inflammation. All these results taken together imply that the mechanism of action of NCX-701 is different from that of paracetamol, although it is not yet established for either molecule. NCX-701 appears to be a promising compound in the treatment of different types of pain, with a likely better profile of side effects than its parent molecule, paracetamol. Although recent clinical trials provided data consistent with the preclinical profile of NCX-701, further studies are needed to support its clinical use.Keywords
This publication has 74 references indexed in Scilit:
- Acetaminophen Recruits Spinal p42/p44 MAPKs and GH/IGF-1 Receptors to Produce Analgesia via the Serotonergic SystemMolecular Pharmacology, 2006
- Effect of a nitric oxide releasing derivative of paracetamol in a rat model of endotoxaemiaBritish Journal of Pharmacology, 2006
- Vitamin A active metabolite, all‐trans retinoic acid, induces spinal cord sensitization. I. Effects after oral administrationBritish Journal of Pharmacology, 2006
- Enhancement of fentanyl antinociception by subeffective doses of nitroparacetamol (NCX-701) in acute nociception and in carrageenan-induced monoarthritisLife Sciences, 2005
- Is Paradoxical Pain Induced by Sustained Opioid Exposure an Underlying Mechanism of Opioid Antinociceptive Tolerance?Neurosignals, 2005
- Attenuation of Morphine Tolerance, Withdrawal-Induced Hyperalgesia, and Associated Spinal Inflammatory Immune Responses by Propentofylline in RatsNeuropsychopharmacology, 2003
- A Critical Appraisal of COX-2 Selective Inhibition and Analgesia: How Good So Far?Pain Practice, 2003
- Acetaminophen distribution in the rat central nervous systemLife Sciences, 2001
- The NSAID dexketoprofen trometamol is as potent as μ-opioids in the depression of wind-up and spinal cord nociceptive reflexes in normal ratsBrain Research, 1999
- Supraspinal influences on the facilitation of rat nociceptive reflexes induced by carrageenan monoarthritisNeuroscience Letters, 1996